1. OS06.5.A Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - the PriCoTTF phase I/II trial. (5th September 2022) Authors: Kebir, S; Lazaridis, L; Schmidt, T; Oster, C; Feldheim, J; Glas, M; Pierscianek, D; Proescholdt, M; Hau, P; Grosu, A; Krex, D; Scheffler, B; Kleinschnitz, C; Pöttgen, C; Stuschke, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P01.012 Tumor Treating Fields (TTFields) in combination with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). (19th September 2018) Authors: Lazaridis, L; Schäfer, N; Kebir, S; Weller, J; Tzaridis, T; Scheffler, B; Pierscianek, D; Kleinschnitz, C; Stuschke, M; Sure, U; Herrlinger, U; Glas, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P01.060 PriCoTTF: a phase I/II trial of Tumor Treating Fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. (19th September 2018) Authors: Glas, M; Scheffler, B; Lazaridis, L; Herrlinger, U; Pierscianek, D; Sure, U; Pröscholdt, M; Hau, P; Hense, J; Kleinschnitz, C; Grosu, A; Stuschke, M; Kebir, S Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P11.14.A Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2021. (5th September 2022) Authors: Oster, C; Lazaridis, L; Feldheim, J; Schmidt, T; Kleinschnitz, C; Kebir, S; Glas, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma. (5th September 2022) Authors: Lazaridis, L; Schmidt, T; Agkatsev, S; Blau, T; Spille, D; Heider, S; Schulz, T; Bumes, E; Oster, C; Feldheim, J; Stummer, W; Kessler, A; Seidel, C; Hau, P; Sure, U; Keyvani, K; Herrlinger, U; Kleinschnitz, C; Stuschke, M; Herrmann, K Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P14.61 Tumor Treating Fields (TTFields) combined with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis. (6th September 2019) Authors: Lazaridis, L; Schäfer, N; Schmidt, T; Stoppek, A; Weller, J; Tzaridis, T; Scheffler, B; Pierscianek, D; Kleinschnitz, C; Stuschke, M; Sure, U; Herrlinger, U; Kebir, S; Glas, M Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P17.04.B Combination of Trofosfamide and Etoposide in Recurrent Glioma. (5th September 2022) Authors: Schmidt, T; Agkatsev, S; Feldheim, J; Oster, C; Blau, T; Sure, U; Keyvani, K; Kleinschnitz, C; Stuschke, M; Hermann, K; Deuschl, C; Scheffler, B; Kebir, S; Glas, M; Lazaridis, L Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis. Issue 12 (16th November 2006) Authors: Meuth, S G; Kleinschnitz, C; Frank, M; Wessig, C; Bendszus, M; Kress, W; Wiendl, H Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 77:Issue 12(2006) Page Start: 1381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗